Department of Pharmacology, Father Muller Medical College, Mangalore, Karnataka, India.
Br J Radiol. 2014 Jun;87(1038):20130490. doi: 10.1259/bjr.20130490. Epub 2014 Apr 2.
The study objective was to assess the effectiveness of a turmeric- and sandal wood oil-containing cream [Vicco(®) turmeric cream (VTC); Vicco Laboratories, Parel, India] on radiodermatitis in patients with head and neck cancer undergoing radiotherapy.
A total of 50 patients with head and neck cancer requiring >60 Gy of curative radiotherapy/chemoradiotherapy were enrolled in the study. The volunteers were randomly divided into two groups of 25 patients. Group 1 was assigned to a topical application of Johnson's(®) baby oil (Johnson & Johnson Ltd, Baddi, India) and Group 2 for VTC. Prophylactic application of the cream was initiated on Day 1 and continued every day until 2 weeks after the end of treatment. Both agents were symmetrically applied within the irradiated field five times a day, and the acute skin reactions were assessed twice weekly in accordance with the Radiation Therapy Oncology Group scores by an investigator who was unaware of the details.
The incidence of radiodermatitis increased with the exposure to radiation and was the highest in both groups at Week 7. However, a significant reduction in grades of dermatitis were seen in cohorts applying VTC at all time points, including 2 weeks post radiotherapy (p < 0.015 to p < 0.001). The occurrence of Grade 3 dermatitis was lower in the cohorts using VTC and was statistically significant (p < 0.01). Additionally, follow-up observations 2 weeks after the completion of radiotherapy also showed a reduced degree of radiodermatitis in cohorts applying VTC, which was significant (p = 0.015).
VTC is shown to be effective in preventing radiodermatitis and needs to be validated in larger double-blind trials.
For the first time, this study shows that the turmeric- and sandal oil-based cream was effective in preventing radiation-induced dermatitis.
本研究旨在评估一种含姜黄和檀香油的乳膏[Vicco(®)姜黄乳膏(VTC);Vicco 实验室,印度帕雷尔]对头颈癌患者放疗后放射性皮炎的疗效。
共纳入 50 例需接受>60 Gy 根治性放疗/放化疗的头颈部癌症患者。志愿者被随机分为两组,每组 25 例。第 1 组给予强生(®)婴儿油(强生有限公司,印度巴迪)局部涂抹,第 2 组给予 VTC。从第 1 天开始预防性涂抹乳膏,持续至治疗结束后 2 周。两种药物均在照射野内对称涂抹,每天 5 次,每周两次由一名不知细节的研究者根据放射治疗肿瘤学组评分评估急性皮肤反应。
随着辐射暴露,放射性皮炎的发生率增加,两组在第 7 周均达到最高。然而,所有时间点应用 VTC 的队列均观察到皮炎分级显著降低,包括放疗后 2 周(p<0.015 至 p<0.001)。应用 VTC 的队列中 3 级皮炎的发生率较低,且具有统计学意义(p<0.01)。此外,放疗完成后 2 周的随访观察也显示应用 VTC 的队列放射性皮炎程度降低,具有统计学意义(p=0.015)。
VTC 被证明可有效预防放射性皮炎,需要在更大的双盲试验中进一步验证。
本研究首次表明,基于姜黄和檀香油的乳膏可有效预防放疗引起的皮炎。